ReviewDigestive diseases and sciences2025
Targeting Lipid Transport Pathways: A New Frontier in Colorectal Cancer Therapy.
Review in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Colorectal cancer (CRC) represents a significant global health challenge, with lipid metabolism emerging as a critical determinant of tumor progression. This review comprehensively examines lipid transport proteins (LTPs) as key regulators of cancer cell metabolism, revealing their complex interactions with cellular processes and the tumor microenvironment. We highlight how LTPs, including fatty acid transport proteins, ATP-binding cassette (ABC) transporters, and solute carrier family proteins, fundamentally influence CRC development through metabolic reprogramming. Notably, altered lipid metabolic pathways enable cancer cells to adapt to high energy demands, with specific transporters like fatty acid transport protein 5(FATP5)and ATP-binding cassette sub-family 12(ABCA12)showing aberrant expression in CRC. Furthermore, emerging evidence suggests intricate relationships between gut microbiota and lipid transport, offering potential diagnostic and therapeutic strategies. The review underscores the potential of LTPs as promising biomarkers and therapeutic targets, emphasizing the need for personalized, multi-omics approaches to comprehensively understand and potentially intervene in CRC progression.
Indexed as
Identifiers
40705243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.